Radiation vs Surgery — How to Think About the Choice

---

One of the most common questions men ask after a prostate cancer diagnosis is whether surgery or radiation gives better cancer control.

The evidence-based answer, supported by multiple large randomised trials, is that for localised and locally advanced prostate cancer, the cancer control rates for surgery and radiation are essentially equivalent.

Neither approach has been proven to cure more men than the other when like-for-like comparisons are made.

What differs between the two is the side effect profile. Surgery carries a higher early risk of urinary incontinence. Radiation carries a higher risk of long-term bowel and bladder irritation, and a small increase in the risk of secondary cancers decades later.

The right choice depends on the patient's age, stage, Gleason score, personal priorities, and medical fitness — not on one approach being objectively better than the other.

Several specific situations tip strongly toward radiation.

Men who are not fit for general anaesthesia, or who have locally advanced disease beyond the prostate capsule, often find radiation to be the better clinical choice.

The same is true for older men concerned about urinary continence recovery, and men who have had pelvic surgery that would make prostatectomy technically difficult.

EBRT and IMRT — Conventional External Beam Radiotherapy

---

External beam radiotherapy delivers high-energy X-ray beams from a machine outside the body, precisely targeting the prostate and — in higher-risk cases — the surrounding lymph nodes and seminal vesicles.

The technique used at India's major cancer centres is intensity-modulated radiotherapy (IMRT), often combined with volumetric arc therapy (VMAT).

These are not different treatments — they are sophisticated delivery methods that shape the radiation beam around the prostate while minimising dose to the bladder, rectum, and bowel.

The linear accelerators delivering this treatment at hospitals like Tata Memorial, Apollo Delhi, Medanta, and Max Saket are Varian TrueBeam and Elekta Infinity systems — the same platforms used at the Christie Hospital in Manchester and Memorial Sloan Kettering in New York.

How many sessions does EBRT take?

A conventional EBRT course for prostate cancer involves 25 to 40 daily treatment sessions delivered Monday to Friday over five to eight weeks.

Each session takes 15 to 20 minutes, the vast majority of which is set-up time. The actual radiation delivery lasts only a few minutes. Patients feel nothing during treatment — there is no pain, heat, or sensation of any kind during the beam delivery.

Moderately hypofractionated schedules — where a higher dose is given per session over a shorter total course — are now standard at most major Indian centres.

These typically involve 20 sessions over four weeks and produce equivalent tumour control with the same or slightly better side effect profile compared to older longer schedules.

What are the side effects?

During and immediately after EBRT, the most common side effects are urinary frequency and urgency — the radiation irritates the bladder lining temporarily. Bowel changes — looser stools, more frequent bowel movements — are also common during the treatment course.

These acute side effects typically peak in the final week of treatment and resolve within two to six weeks of completion. They are uncomfortable but manageable, and most patients continue their normal daily activities throughout the treatment course.

Long-term side effects — which affect a minority of patients — include late radiation cystitis, bowel changes, and a small risk of secondary pelvic cancers from the radiation exposure.

These are uncommon but real, and they should be part of the informed consent discussion.

Who is EBRT best suited for?

EBRT is appropriate for men across all risk groups — low, intermediate, and high risk — and for locally advanced disease where the cancer has grown into the seminal vesicles or pelvic lymph nodes.

For high-risk locally advanced disease, EBRT combined with long-course hormone therapy (ADT) is the standard of care — this combination consistently outperforms either treatment alone in terms of disease control and survival.

EBRT is also the standard salvage treatment when PSA rises after radical prostatectomy — delivering radiation to the prostate bed where cancer cells may have remained after surgery.

SBRT and CyberKnife — Five Sessions, Same Outcomes

---

Stereotactic body radiotherapy — SBRT, sometimes called SABR — delivers the entire radiation course in five sessions rather than the 20 to 40 of conventional EBRT.

Each session delivers a much higher dose of radiation per fraction, precisely targeted at the prostate with sub-millimetre accuracy. The biological effect on the tumour is equivalent to a full conventional course — the difference is only in how the dose is divided and delivered.

The PACE-B trial — a large randomised study published in The Lancet — confirmed that five-fraction SBRT is non-inferior to conventional or moderately hypofractionated radiotherapy for low-risk and intermediate-risk localised prostate cancer in terms of five-year disease control.

What is CyberKnife and how is it different from SBRT?

CyberKnife is a specific brand of robotic radiosurgery system manufactured by Accuray. It delivers SBRT using a robotic arm that can position the radiation beam from hundreds of different angles — providing exceptional conformality around the prostate.

The key feature of CyberKnife for prostate treatment is real-time tumour tracking. The system continuously monitors the position of the prostate during each treatment session using implanted gold fiducial markers or Calypso transponders.

The prostate moves slightly with breathing, bowel filling, and patient movement.

Conventional radiation systems account for this by adding a margin around the prostate to ensure the tumour is always in the beam. CyberKnife tracks the prostate in real time and adjusts the beam to follow it, allowing a tighter margin and less radiation to surrounding tissue.

In terms of cancer control outcomes, CyberKnife SBRT and linac-based SBRT produce equivalent results.

The difference is in the precision of delivery and margin size, which may translate to slightly lower rates of urinary and bowel side effects in some studies.

Why SBRT is the most practical option for international patients

Five treatment sessions over one to two weeks means a total stay in India of ten to fourteen days including pre-treatment preparation, simulation, and the sessions themselves.

For a patient flying from Nigeria, the UK, or the UAE, this is the difference between a two-week trip and a two-month stay. The cancer control outcome is the same. The logistics are dramatically simpler.

SBRT is available at Kokilaben Dhirubhai Ambani Hospital in Mumbai (CyberKnife), Apollo Hospitals Delhi, Fortis FMRI Gurgaon, and HCG Hospitals.

For patients with low-to-intermediate-risk localised prostate cancer who are travelling to India, SBRT is consistently the treatment option GAF Healthcare evaluates first from a practical standpoint.

Who is SBRT suited for — and who is not?

SBRT is appropriate for low-risk and intermediate-risk localised prostate cancer — disease confined to the prostate without significant extracapsular extension.

Men with very large prostate glands — typically above 100 grams — may not be suitable because the prostate can extend into the high-dose beam path in a way that increases urinary side effects.

Men with locally advanced disease extending into the seminal vesicles or lymph nodes generally need conventional EBRT with a longer course and higher total dose rather than SBRT alone.

Pre-treatment preparation for SBRT includes fiducial marker placement — small gold markers placed inside the prostate under ultrasound guidance, one to two weeks before treatment begins.

These markers allow the radiation team to precisely locate the prostate position at each session.

Brachytherapy — Radiation From Inside the Prostate

---

Brachytherapy is fundamentally different from external beam techniques. Instead of directing radiation at the prostate from outside the body, brachytherapy places radioactive sources directly inside the prostate tissue.

This delivers an extremely high radiation dose to the prostate itself while the dose falls off rapidly in the surrounding tissue — protecting the bladder, rectum, and urethra better than any external approach can achieve for the same tumour dose.

Low-dose-rate brachytherapy (LDR) — the permanent seed implant

In low-dose-rate brachytherapy, between 60 and 120 small radioactive seeds — each about the size of a grain of rice — are permanently implanted into the prostate under ultrasound guidance.

The seeds are most commonly iodine-125 or palladium-103. They emit low-energy radiation continuously for several months, gradually losing their radioactivity as the cancer dose is delivered. The seeds remain in the prostate permanently but become inert within a year.

The implant procedure is performed under general or spinal anaesthesia as a day case or overnight admission. The patient goes home the same day or the following morning with a urinary catheter, which is removed within 24 hours.

LDR brachytherapy is suitable for low-risk and selected favourable intermediate-risk localised prostate cancer.

The fifteen-year disease control data for LDR brachytherapy in these groups is outstanding — equivalent to radical prostatectomy and external beam radiation in the published literature.

High-dose-rate brachytherapy (HDR) — temporary, high-precision delivery

In high-dose-rate brachytherapy, hollow catheters are temporarily placed through the perineum into the prostate under anaesthesia.

A single high-activity iridium-192 source is driven through each catheter in sequence, pausing at pre-planned positions to deliver a precisely calculated dose.

The entire treatment takes one to three hours. The catheters are removed immediately afterwards — nothing remains in the prostate.

HDR brachytherapy is almost always combined with external beam radiation for high-risk localised or locally advanced disease — as a boost after the EBRT course to deliver an intensified dose to the prostate itself.

This combination — EBRT plus HDR boost — produces excellent long-term outcomes for high-risk disease and is used at Tata Memorial Hospital and Apollo Delhi, among others.

What are the side effects of brachytherapy?

The most common short-term side effect of LDR seed implant is urinary symptoms — frequency, urgency, and a weakened stream. These occur because the seeds cause local swelling and irritation of the prostate tissue around the urethra.

These symptoms typically peak in the first four to six weeks after implant and gradually resolve over three to six months. Alpha-blocker medication helps manage them during this period.

Men with very large prostates or severe pre-existing urinary symptoms — significant BPH — are generally not good candidates for LDR brachytherapy because the seed implant can cause acute urinary retention requiring catheterisation.

Radiation Combined With Hormone Therapy — When and Why

---

For intermediate-risk and high-risk prostate cancer, radiation therapy alone is not the standard of care.

Multiple large randomised trials — the RTOG studies, the EORTC 22863 trial — have demonstrated that adding androgen deprivation therapy (ADT) to radiation therapy significantly improves both disease-free survival and overall survival compared to radiation alone.

ADT reduces testosterone to near-zero levels. Prostate cancer cells need testosterone to grow.

Removing that fuel while delivering radiation creates a combined attack that dramatically improves outcomes in intermediate and high-risk groups.

How long does hormone therapy run alongside radiation?

The duration depends on your risk group. For favourable intermediate-risk disease, short-course ADT of four to six months is standard — typically starting one to two months before radiation and continuing during the course.

For unfavourable intermediate-risk and high-risk localised disease, long-course ADT of 18 to 36 months is recommended. For locally advanced disease with nodal involvement, ADT may continue for two to three years or longer.

The hormonal therapy component is administered by injection — LHRH agonists given every one, three, or six months.

This part of the treatment can be initiated in India and then continued at home through a local oncologist, with the injections given in your home country at a fraction of India's already low cost.

What are the side effects of ADT alongside radiation?

The main side effects of ADT are hot flushes, fatigue, loss of libido, and gradual bone density loss with prolonged use.

These are manageable but real, and they affect quality of life during the treatment period. For short-course ADT of four to six months, most men find the side effects tolerable and most reverse within six to twelve months of stopping.

For long-course ADT, bone density monitoring and supplementation with calcium and vitamin D are recommended from the outset. Regular cardiovascular monitoring is also important, as long-term ADT increases metabolic syndrome risk.

EBRT vs SBRT vs Brachytherapy — Comparison for International Patients

---

For an international patient, the practical differences between these three modalities are as important as the clinical differences.

The stay required in India, the daily commitment during treatment, and the logistics of returning home all vary substantially between them.

Factor	EBRT / IMRT	SBRT / CyberKnife	Brachytherapy (LDR)
Sessions	20–40 daily sessions	5 sessions	1 procedure
Stay in India	5–8 weeks	10–14 days	7–10 days
Suitable stages	All risk groups incl. locally advanced	Low–intermediate risk, localised	Low–favourable intermediate, localised
ADT required?	Yes (intermediate-high risk)	Sometimes (intermediate risk)	Sometimes (unfavourable intermediate)
Cancer control (5-yr)	~90–95% (localised)	~90–95% (localised)	~90–95% (low risk)
Urinary side effects	Moderate during treatment; resolves	Mild to moderate; usually resolves	Significant short-term; 3–6 months
Large prostate suitable?	Yes	Often not (>100g)	Often not (>60g)
Cost in India	USD 4,000–7,000	USD 5,000–9,000	USD 4,000–7,500

Costs in India vs UK and USA

---

Radiation therapy for prostate cancer in India costs 60 to 80 percent less than equivalent treatment in the United States or the United Kingdom.

This saving is not because India uses older or less capable equipment. The Varian TrueBeam and Elekta Infinity systems at Apollo, Medanta, and Max Saket are the same generation and specification as the machines in use at the Christie in Manchester or MD Anderson in Houston.

The difference is structural — India's healthcare labour costs, infrastructure, and administrative overhead are fundamentally lower than in Western healthcare markets.

Treatment	India (JCI hospital)	USA (private)	UK (private)
EBRT / IMRT (full course)	USD 4,000–7,000	USD 30,000–60,000	GBP 15,000–28,000
SBRT / CyberKnife (5 sessions)	USD 5,000–9,000	USD 25,000–50,000	GBP 12,000–20,000
LDR brachytherapy (seed implant)	USD 4,000–7,500	USD 15,000–30,000	GBP 10,000–18,000
HDR brachytherapy boost	USD 3,000–5,500	USD 12,000–25,000	GBP 8,000–15,000
EBRT + HDR boost (combined)	USD 7,000–12,000	USD 40,000–80,000	GBP 20,000–35,000
ADT injection (LHRH, monthly)	USD 80–150/month	USD 800–1,500/month	GBP 400–900/month
PSMA PET-CT (pre-treatment staging)	USD 500–900	USD 3,000–6,000	GBP 2,500–4,000

For an SBRT patient, the total India trip cost — including ten to fourteen days' accommodation at USD 40 to 70 per night, flights, and treatment — typically stays well under USD 12,000 from the UK or UAE.

For a conventional EBRT patient who needs to stay five to eight weeks, accommodation costs are higher — but the treatment cost remains 70 to 80 percent below what the same course costs in the United States.

Read the full cost guide: Prostate cancer treatment cost in India — complete breakdown for international patients →

Planning Radiation Treatment in India — Practical Guide for International Patients

---

Radiation therapy requires more upfront planning than surgery — not because the procedure itself is more complex, but because each patient's treatment plan is individually calculated.

The radiation oncologist needs your imaging, biopsy, and PSA history before they can design your plan. A CT simulation scan — which maps your prostate anatomy for treatment planning — is done on arrival in India, typically one to two weeks before treatment starts.

What to bring and send in advance

Before travelling, send your full PSA history, biopsy pathology report with Gleason score, and multiparametric MRI of the prostate.

A PSMA PET-CT is particularly valuable for staging before radiation — if you have not had one, India can do this on arrival at a fraction of the cost elsewhere.

GAF Healthcare reviews your reports before you travel, confirms the right treatment plan and modality, and arranges a video consultation with your radiation oncologist. You arrive in India with a confirmed plan — not to start the evaluation process from scratch.

Timeline from arrival to first treatment

For SBRT with fiducial markers: day one, consultation and marker insertion. One week wait for prostate settling. Then five treatment sessions over one to two weeks. Total stay: ten to fourteen days.

For conventional EBRT: day one, consultation and CT simulation. Three to five days for treatment planning. Daily treatment for four to eight weeks. Total stay matches the treatment course duration.

For LDR brachytherapy: pre-treatment transrectal ultrasound volumetry, then procedure under anaesthesia, overnight or day-case admission, discharge the following morning. Total stay: seven to ten days.

Which hospitals offer each modality?

SBRT and CyberKnife: Kokilaben Dhirubhai Ambani Hospital Mumbai (CyberKnife), Apollo Hospitals New Delhi, Fortis FMRI Gurgaon, HCG Hospitals.

EBRT / IMRT / VMAT: All six hospitals recommended by GAF Healthcare — Medanta, Max Saket, Apollo Delhi, Fortis FMRI, Kokilaben, and Artemis Gurgaon.

LDR brachytherapy: Tata Memorial Hospital Mumbai, Apollo Delhi, Fortis FMRI. HDR brachytherapy boost: Tata Memorial, Apollo, Medanta.

Read the full hospital comparison: Best hospitals for prostate cancer in India — Fortis, Medanta, Apollo, Artemis, Max and Kokilaben compared →

"I could not have five weeks of daily radiotherapy away from my family and job. When GAF Healthcare explained that SBRT was five sessions over a week and the cancer control was the same, I could not believe it was possible. I was back home in Lagos fourteen days after arriving in India. My PSA is undetectable."

— Mr. S. O., 61, Nigeria · SBRT for localised prostate cancer, Apollo Delhi, March 2025